Introduction
============

Systemic sclerosis (SSc) is a rare rheumatic disease in which vasculopathy, tissue fibrosis and autoimmunity are pathophysiological features that lead to specific forms of organ damage. According to LeRoy criteria patients with SSc can present with skin thickening proximal to the elbow and knee in diffuse cutaneous SSc (dcSSc) or with skin thickening restricted to areas distal to the elbow and knee in limited cutaneous SSc (lcSSc) ([@b1-etm-0-0-8125]). Involvement of the gastrointestinal tract (GIT) is one of the common systemic manifestations of SSc, besides skin findings and Raynaud\'s phenomenon ([@b2-etm-0-0-8125]). Gastroesophageal manifestations, present both in lcSSc and dcSSc, may significantly affect the quality of life and in rare cases they can cause lethal complications ([@b3-etm-0-0-8125]). Data from a Central-Eastern Europe cohort support the hypothesis that the GIT involvement is more frequent than expected ([@b3-etm-0-0-8125]). Moreover, in a multicenter collaboration analysis of 7,655 patients, on the large European League Against Rheumatism Scleroderma Trials and Research (EUSTAR) cohort, upper GIT manifestations were more frequently described, as compared to lower GIT symptoms ([@b4-etm-0-0-8125]). Both the esophagus and the stomach can be involved resulting in a variety of symptoms from dysphagia and regurgitation to retrosternal burning pain, early satiety and epigastric pain ([@b2-etm-0-0-8125]).

As clinical symptoms are non-specific and the diagnosis is often delayed, upper gastrointestinal (GI) endoscopy is used to highlight the substrate of these symptoms, which usually is esophagitis or gastritis. If left untreated, they may lead to further complications such as ulceration on the esophagus and the stomach, Barrett\'s esophagus, benign esophageal strictures and adenocarcinoma, which also can be diagnosed by endoscopy ([@b5-etm-0-0-8125],[@b6-etm-0-0-8125]). Upper GI endoscopy is also useful in diagnosing gastric antral vascular ectasia (GAVE) and candidiasis in SSc patients ([@b6-etm-0-0-8125],[@b7-etm-0-0-8125]). GAVE or 'watermelon stomach' has a unique endoscopic appearance, with prominent multiple red vessels in a stripe pattern, radiating from the antrum to the pylorus ([@b8-etm-0-0-8125]).

The main goal of the present study was to describe gastroesophageal endoscopic and histopathological findings in patients with SSc irrespective of the presence of gastroesophageal symptoms. Differences between dcSSc and lcSSc in terms of upper GIT involvement were compared.

Materials and methods
=====================

### Study population

In this cross-sectional study, 79 consecutive patients with SSc attending the inpatient clinic of the Rheumatology Department of the Emergency Clinical County Hospital (Cluj-Napoca, Romania) between November 2016 and December 2018 were enrolled. All patients met the ACR/EULAR 2013 classification criteria for SSc ([@b9-etm-0-0-8125]). We assessed esophagitis and gastritis from a clinical, endoscopic and histopathological point of view.

Study approval was obtained from the institutional ethics review board and all subjects signed a written informed consent according to the Declaration of Helsinki.

Exclusion criteria were: i) severe cardiopulmonary involvement (i.e., restrictive lung disease); ii) diabetes, iii) bisphosphonate use; iv) active smokers; v) patients with current alcohol consumption; and vi) patients with markedly reduced oral aperture, who were unable to secure mouth guard during the endoscopic procedure.

### Data collection

Data were collected regarding demographic and clinical features, including information on age, gender, disease duration (defined as the onset of the first non-Raynaud\'s symptom), type of skin involvement, presence or absence of gastroesophageal symptoms (heartburn, acid regurgitation, dysphagia, early satiety, epigastric pain), the presence of cardiovascular, pulmonary and renal manifestations. The presence of digital ulcers, calcinosis, telangiectasias, arthritis, anemia, dyslipidemia and current or previous medication intake were also collected from all subjects.

Routine laboratory studies included C-reactive protein (CRP) levels. Antinuclear, anticentromere and anti-topoisomerase-I antibodies were measured.

### Upper gastrointestinal endoscopy

All SSc patients, irrespective of the presence or absence of gastroesophageal symptoms, underwent upper GI endoscopy for detection of esophageal and gastric mucosa lesions. Endoscopy was performed after an overnight fast using an Olympus videogastroscope EVIS EXERA III (GIF-HQ190).

Mucosal damage of the esophagus was classified according to the Los Angeles (LA) Classification ([@b9-etm-0-0-8125]). The diagnosis of esophageal candidiasis was made by endoscopy and was defined by the presence of white or slightly yellowish plaque- like lesions on the esophageal mucosa as described in a previous study ([@b10-etm-0-0-8125]). Barrett\'s esophagus was defined by the presence of a specialized columnar epithelium with a minimum length of 1 cm (tongues or circular) into the distal esophagus and the presence of specialized intestinal metaplasia on histopathological examination in accordance to recent European Society of Gastrointestinal Endoscopy guidelines ([@b11-etm-0-0-8125]). In addition, the presence or absence of a hiatal hernia was noted.

An abnormal-appearing gastric mucosa (edema, erythema, friability, erosions, fold enlargement, fold atrophy, visibility of the vascular pattern, intramural bleeding, nodularity) was defined as gastritis on endoscopy ([@b12-etm-0-0-8125]). To establish a definitive diagnosis of gastritis, minimum four biopsies were taken from the gastric mucosal tissue (2 from the antrum and 2 from corpus) using a standard biopsy forceps. Additional biopsies were taken from any area of abnormality.

The histopathological examination assessed the presence of polymorphonuclear leucocytes alongside the mononuclear inflammatory infiltrate, intestinal metaplasia, atrophy characterized by the loss of the normal mucosal glands. The presence of *Helicobacter pylori* (HP) organisms was also assessed on histopathological examination.

### Statistical analysis

Statistical analysis was performed with SPSS version 21 (SPSS Inc., Chicago, IL, USA). P\<0.05 was considered to indicate a statistically significant difference. Results are expressed as the mean (standard deviation) for continuous numerical data, median (25.75 percentiles) for discrete numerical data or frequency (percentage) for categorical variables. The normality distribution test was performed with the aid of the Shapiro-Wilk test. Comparisons across groups were performed with the Student\'s t-test for normally distributed data and with Mann-Whitney U test for those that were not following normal distribution. The Chi-square test was used to compare frequencies among the populations.

Results
=======

A total of 79 eligible SSc patients were enrolled: 7 males (8.8%) and 72 females (91.1%). The mean age was 53.4±9.8 years (range, 23--77). The median disease duration at the time of the study was 6.01 years. A total of 44 (55.6%) patients had lcSSc and 35 (44.3%) had dcSSc. A majority of these patients (94.9%) received a disease-modifying antirheumatic drugs (DMARDs). Among DMARDs, methotrexate was the most frequently prescribed (46.8%), followed by azathioprine (43.1%) and cyclophosphamide (29.1), in association with corticosteroids (44%) and non-steroidal anti-inflammatory drugs (NSAIDS) (32.9%). There was no association between drug intake and gastroesophageal symptoms or endoscopic findings (data not shown). Demographics, clinical data and medication use in the two subsets of patients are shown in [Table I](#tI-etm-0-0-8125){ref-type="table"}.

The most frequent upper gastrointestinal manifestations were dysphagia, present in 16 (36.4%) lcSSc and 17 (48.6%) dcSSc patients, and gastroesophageal reflux in 10 (22.7%) lcSSc and 13 (37.1%) dcSSc patients. Endoscopic examination revealed that esophagitis (LA classification A-D) was present in 19 (43.1%) of lcSSc patients and 20 (57.1%) of those with dcSSc. Twelve out of 26 (52.1%) patients with gastroesophageal reflux symptoms had esophagitis on endoscopy. There were no statistically significant differences between patients with lcSSc and patients with dcSSc in terms of gastroesophageal symptoms, endoscopic findings and esophagitis grading ([Table II](#tII-etm-0-0-8125){ref-type="table"}). Barrett\'s esophagus was diagnosed by endoscopy, according to predefined criteria in 8 patients, but only 2 of those with dcSSc and 3 of those with lcSSc were histopathologically confirmed. In one case the endoscopy could not evaluate the stomach due to the presence of esophageal stenosis. Forty-five (56.9%) patients had gastric abnormalities on endoscopic evaluation and were confirmed by histopathological examinations. Thirteen (16.4%) patients were positive for HP on direct histopathological visualization. Thirty-one (39.2%) patients had no signs of gastritis on endoscopy, but histopathological signs of gastritis such as inflammatory plasma cells, lymphocytes, neutrophil infiltration and intestinal metaplasia were present in 18 (22.7%) of them. There were no significant statistical differences between those with lcSSc and respectively those with dcSSc in terms of endoscopic or histopathological gastritis (P=0.2 and 0.4, respectively, in the Chi-Square test). Endoscopic appearance of watermelon stomach was found in 2 patients and of esophageal candidiasis in 4. Sixty-five out of 79 patients were treated with proton pump inhibitors (PPI) (Omeprazole 20 mg/day, mean duration of administration was 8.9 months). Thirty-seven out of these 65 patients (56.9%) had esophagitis and 46 (70.7%) had gastritis. There were no significant statistical differences between clinical or endoscopic findings and age, disease duration or other disease variables.

In total, 22 patients (27.8%) were asymptomatic concerning gastroesophageal manifestations, but in 72.7% endoscopic changes were found. There were no statistically significant differences between symptomatic and asymptomatic patients in terms of endoscopic and histopathological findings ([Table III](#tIII-etm-0-0-8125){ref-type="table"}), except the significantly higher presence of hiatal hernia in symptomatic patients (P=0.01).

Discussion
==========

The purpose of this study was to assess gastroesophageal involvement in a group of 79 consecutive SSc patients using upper GI endoscopy. Possible differences were evaluated between the subtypes of the disease, regardless of the presence or absence of symptoms. Several publications assessing GI damage in patients with SSc suggest a high prevalence of gastroesophageal involvement (estimated up to 90%) ([@b13-etm-0-0-8125]). Some studies highlighted the fact that SSc patients showed damage in the upper GI tract even in the absence of symptoms and early in the disease ([@b14-etm-0-0-8125]--[@b16-etm-0-0-8125]). In our study, gastroesophageal symptoms were present in 72.1% of cases, both in early and late stages of the disease. A large proportion of asymptomatic patients (72.7%) experienced esophageal and gastric changes in endoscopy.

The average age of disease onset for SSc in our study was 47.3 years (similar to the EUSTAR update report) ([@b4-etm-0-0-8125]). The disease duration of the majority of our patients (64.5%) was under 6 years. Dysphagia was present in 33 (41.7%) patients and gastroesophageal reflux symptoms in 23 (29.1%) patients, while both symptoms were present in 13 cases (16.4%), similar when compared with other studies ([@b17-etm-0-0-8125]--[@b19-etm-0-0-8125]). The relationship between esophageal symptoms and the subtype of SSc is controversial. Lahcene *et al* ([@b17-etm-0-0-8125]) found that esophageal complaints were significantly more frequent in dcSSc, while in studies of Bassotti *et al* ([@b20-etm-0-0-8125]) and Akesson and Wollheim ([@b13-etm-0-0-8125]), as well as in our work, they were not related with disease subtype.

In total, 19 patients (24.05%) were found with hiatal hernia on endoscopy, with significantly higher frequency of hiatal hernia in symptomatic patients (94%) and in the diffuse disease subtype (63.1%). Similar results were observed in other studies in patients with SSc ([@b3-etm-0-0-8125],[@b21-etm-0-0-8125],[@b22-etm-0-0-8125]). Also, association between hiatal hernia and reflux symptoms, reflux esophagitis, Barrett\'s esophagus and esophageal adenocarcinoma was observed in several studies in the general population ([@b23-etm-0-0-8125]--[@b25-etm-0-0-8125]).

In our study, reflux esophagitis was found in 40 cases (50.6% of the patients), similar with the prevalence reported in several previous recent studies ([@b17-etm-0-0-8125],[@b19-etm-0-0-8125]). Complications of reflux esophagitis such as esophageal stenosis, Barrett esophagus and esophageal adenocarcinoma are increased in SSc ([@b26-etm-0-0-8125]). In our study, Barrett esophagus has been endoscopically described in 8 (10.1%) cases but only 5 cases have been histopathologically confirmed. The prevalence of Barrett\'s esophagus reported in some retrospective studies varies between 2 and 37% ([@b26-etm-0-0-8125]--[@b28-etm-0-0-8125]). Data on the effects of PPI treatment on esophageal and gastric mucosal inflammation in SSc patients are heterogeneous. PPI treatment with maximal doses (lansoprazole 2 × 30 mg or pantoprazole 2 × 40 mg) is useful for long-term safety and reduces the length of Barrett esophagus ([@b29-etm-0-0-8125]). Some other reports suggested that patients with SSc should be encouraged to receive early and long-term PPI treatment ([@b14-etm-0-0-8125],[@b19-etm-0-0-8125]). Thonhofer *et al* ([@b14-etm-0-0-8125]) showed in a small group of patients with early SSc who received adequate PPI therapy and antibiotic therapy for elimination of HP, complete mucosal healing in the distal esophagus and stomach ([@b14-etm-0-0-8125]). On the contrary, Hendel *et al* ([@b6-etm-0-0-8125]) reported that complete healing of esophagitis occurs only in half of the patients with SSc and severe gastroesophageal reflux disease receiving intensive PPI treatment. The results of our study showed that, although a large proportion of patients were under PPI treatment at the time of endoscopy, most of them had esophagitis and/or gastritis. This could be explained by the administration of low doses of PPI and the use of concomitant medication (such as NSAIDS, DMARDs, Bosentan). There was one case of esophageal stenosis and no case of adenocarcinoma observed in our study.

Although there have been several publications addressing the frequency and intensity of gastric symptoms in SSc patients, the majority focused on the evaluation of delayed gastric emptying, gastroparesis and the presence of GAVE. In our study, the focus was on the presence of gastritis in SSc patients, which was encountered at endoscopy in 47 (59.4%) and histopathologically confirmed in 45 patients. In 18 patients gastritis was detected only after histopathological examination. In a Central-Eastern Europe cohort, gastritis was present in 18.3% of SSc patients ([@b3-etm-0-0-8125]). In a retrospective study by Thonhofer *et al* ([@b14-etm-0-0-8125]), 12 out of 13 patients with early SSc without GE symptoms had endoscopic gastritis. This wide range of prevalence in diagnosis of gastritis could be due to differences between diagnosis protocols and different PPI usage in the above studies.

HP is commonly associated with various autoimmune diseases, but its role in inducing them is controversial ([@b30-etm-0-0-8125],[@b31-etm-0-0-8125]). Some data suggest that HP infection is correlated with SSc activity and skin involvement ([@b32-etm-0-0-8125]). In our patients, we did not find any differences between dcSSc and lcSSc regarding the presence of HP. Despite the fact that in the last decades there has been a decline in the prevalence of chronic gastritis and HP infection, their frequency in East European countries remain high (68.9% in Romania and 66.6% in Poland for HP prevalence) ([@b33-etm-0-0-8125]). The prevalence of HP infection in our study was 15.1%, much lower than we expected ([@b31-etm-0-0-8125],[@b32-etm-0-0-8125]), probably due to continuous PPI treatment.

Our study highlights the fact that SSc patients with or without gastroesophageal symptoms should be endoscopically evaluated, given that patients experience esophageal and gastric disease irrespective of disease duration or the presence of PPI treatment. We still need more studies to evaluate when and how often endoscopy should we performed.

The main limitation of our study is the relatively small sample size and the fact that endoscopy was performed at different stages of the disease. Also, our cohort was heterogeneous in terms of disease duration and disease-related complications and many of our patients were undergoing PPI, DMARDS or NSAIDS treatment which could have influenced the results.

Our data support the results of other authors, according to which SSc patients often have gastroesophageal involvement during the early phase of the disease and in the absence of symptoms. Our data also suggest that PPI treatment can be the cause of the lack of symptoms in those with endoscopic gastroesophageal damage.

In conclusion, upper GI involvement was frequent in SSc patients, with no significant differences between dcSSc and lcSSc. Endoscopic changes were present in the majority of the asymptomatic patients. Our findings suggest the need of upper GI endoscopy in the management of SSc patients.
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###### 

Patient and disease characteristics.

  Characteristics              lcSSc n=44 (%)   dcSSc n=35 (%)   P-value
  ---------------------------- ---------------- ---------------- ---------
  Age                          55.1 (10.6)      51.29 (11.3)     0.1
  Female                       43 (97.7)        29 (82.9)        0.04
  Disease duration (years)     6.73 (5)         5.1 (4.2)        0.1
  ANA positivity               43 (97.7)        34 (97.1)        0.9
  Capillaroscopy pattern                                         
    Normal                     1 (2.3)          1 (2.8)          0.5
    Early                      17 (38.6)        9 (25.7)         
    Active                     18 (40.9)        18 (51.4)        
    Late                       8 (18.2)         6 (17.1)         
  Rodnan score                 4 (2;8)          12.5 (6;17)      \<0.001
  6MWT n (%)                   372 (109)        344 (125)        0.1
  Presence of telangiectasia   32 (72.7)        19 (54.3)        0.08
  NSAID use                    14 (31.8)        12 (34.3)        0.8
  Arthralgia                   32 (72.7)        27 (77.1)        0.4
  Arthritis                    9 (20.5)         8 (22.9)         0.5
  PPI use prior to UE          34 (77.3)        30 (85.7)        0.3
  Bosentan/Sildenafil          7 (15.9)         4 (11.4)         0.5

Numerical data are expressed as mean (SD) and categorical data as no. (%). lcSSc, limited cutaneous systemic sclerosis; dcSSc, diffuse cutaneous systemic sclerosis; ANA, antinuclear antibodies; 6MMWT, 6 minutes walking test; NSAID, non steroidal antiinflammatory drug; PPI, proton pump inhibitor; UE, upper endoscopy.

###### 

Main clinical and endoscopic findings in patients with lcSSc compared to patients with dcSSc.

  Characteristics             lcSSc n=44 (%)   dcSSc n=35 (%)   P-value
  --------------------------- ---------------- ---------------- ---------
  GE symptoms                 32 (72.7)        25 (71.4)        0.8
  Dysphagia                   16 (36.4)        17 (48.6)        0.3
  GE reflux                   10 (22.7)        13 (37.1)        0.3
  Nausea/Vomiting             2 (4.5)          4 (11.4)         0.3
  Early satiety               3 (6.8)          5 (14.3)         0.4
  Epigastric pain             7 (15.9)         3 (8.6)          0.5
  Hiatal hernia               7 (15.9)         12 (34.2)        0.06
  Esophagitis                                                   
    Class A                   7 (15.9)         11 (31.4)        0.2
    Class B                   8 (18.2)         4 (11.4)         
    Class C                   3 (6.8)          2 (5.7)          
    Class D                   1 (2.3)          3 (8.6)          
  Barrett esophagus           4 (9.1)          4 (11.4)         0.7
  Endoscopic gastritis        29 (65.9)        19 (54.2)        0.8
  Histopathologic gastritis   37 (84.1)        27 (77.1)        0.7
  HP positive                 7 (15.9)         5 (14.3)         0.6
  Esophageal ulcer            4 (9.1)          1 (2.9)          0.2
  Intestinal metaplasia       4 (9.1)          3 (8.6)          0.9

Data are expressed as nο. (%). lcSSc, limited cutaneous systemic sclerosis; dcSSc, diffuse cutaneous systemic sclerosis; GE, gastroesophageal; HP, *Helicobacter pylori*.

###### 

Comparison of symptomatic and asymptomatic patients in terms of endoscopic and histopathological findings.

  Values                      Symptomatic n=57 (%)   Asymptomatic n=22 (%)   P-value
  --------------------------- ---------------------- ----------------------- ---------
  Hiatal hernia               18 (31.6)              1 (4.5)                 0.01
  Gastric polyps              6 (10.5)               1 (4.5)                 0.4
  Metaplasia                  5 (8.8)                2 (9.1)                 0.9
  Esophageal ulcers           4 (7)                  1 (4.5)                 0.6
  HP positivity               8 (14)                 5 (2.7)                 0.3
  Endoscopic gastritis        43 (75.4)              13 (59.1)               0.2
  Histopathologic gastritis   46 (80)                18 (81)                 0.9
  Barrett esophagus           7 (12.3)               1 (4.5)                 0.3
  Esophagitis                 31 (54.4)              8 (36.4)                0.2

Data are expressed as n (%). HP, *Helicobacter pylori*.
